dc.contributor.author | Pece, S | |
dc.contributor.author | Sestak, I | |
dc.contributor.author | Montani, F | |
dc.contributor.author | Tillhon, M | |
dc.contributor.author | Maisonneuve, P | |
dc.contributor.author | Freddi, S | |
dc.contributor.author | Chu, K | |
dc.contributor.author | Colleoni, M | |
dc.contributor.author | Veronesi, P | |
dc.contributor.author | Disalvatore, D | |
dc.contributor.author | Viale, G | |
dc.contributor.author | Buus, R | |
dc.contributor.author | Cuzick, J | |
dc.contributor.author | Dowsett, M | |
dc.contributor.author | Di Fiore, PP | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2022-09-05T11:44:30Z | |
dc.date.available | 2022-09-05T11:44:30Z | |
dc.date.issued | 2022-03-01 | |
dc.identifier | S0959-8049(22)00007-7 | |
dc.identifier.citation | European Journal of Cancer, 2022, 164 pp. 52 - 61 | en_US |
dc.identifier.issn | 0959-8049 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5408 | |
dc.identifier.eissn | 1879-0852 | |
dc.identifier.eissn | 1879-0852 | |
dc.identifier.doi | 10.1016/j.ejca.2022.01.003 | |
dc.description.abstract | OBJECTIVE: Molecular tests predicting the risk of distant recurrence (DR) can be used to assist therapy decision-making in oestrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer patients after considerations of standard clinical markers. The Oncotype DX Recurrence Score (RS) is a widespread tool used for this purpose. Here, we compared the RS with the StemPrintER Risk Score (SPRS), a novel genomic predictor with a unique biological basis in its ability to measure the expression of cancer stemness genes. MATERIALS AND METHODS: We benchmarked the SPRS vs. RS, alone or in combination with clinicopathological variables expressed by the Clinical Treatment Score (CTS), for the prognostication of DR in a retrospective cohort of 776 postmenopausal patients with ER+/HER2-breast cancer enrolled in the translational arm of the randomised Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial. Likelihood ratio (LR) with χ2 test and C-index were used to assess prognostic performance for the entire ten-year follow-up period and in early (0-5 years) and late (5-10 years) intervals. RESULTS: In all patients, the SPRS provided significantly more prognostic information than the RS for ten-year DR prognostication (C-index = 0.688, LR-χ2 = 33.4 vs. C-index = 0.641, LR-χ2 = 22.1) and for late (5-10 years) DR prognostication (C-index = 0.689, LR-χ2 = 18.8 vs. C-index = 0.571, LR-χ2 = 4.7). The SPRS also provided more prognostic information than the RS when added to the CTS in all patients (CTS + SPRS: LR-Δχ2 = 14.9; CTS + RS: LR-Δχ2 = 9.7) and in node-negative patients (CTS + SPRS: LR-Δχ2 = 11.7; CTS + RS: LR-Δχ2 = 6.6). CONCLUSIONS: In postmenopausal ER+/HER2- breast cancer patients, SPRS provided more prognostic information than RS for DR when used alone or in combination with the CTS. The SPRS could therefore potentially identify high-risk patients, who might benefit from aggressive treatments, from low-risk patients who might safely avoid adjuvant chemotherapy or prolongation of endocrine therapy. | |
dc.format | Print-Electronic | |
dc.format.extent | 52 - 61 | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | ELSEVIER SCI LTD | en_US |
dc.relation.ispartof | European Journal of Cancer | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | en_US |
dc.subject | Biomarkers | |
dc.subject | Breast cancer | |
dc.subject | Cancer stem cells | |
dc.subject | Metastasis | |
dc.subject | Prognostic genomic tools | |
dc.subject | Anastrozole | |
dc.subject | Biomarkers, Tumor | |
dc.subject | Breast Neoplasms | |
dc.subject | Female | |
dc.subject | Humans | |
dc.subject | Neoplasm Recurrence, Local | |
dc.subject | Prognosis | |
dc.subject | Receptor, ErbB-2 | |
dc.subject | Retrospective Studies | |
dc.subject | Tamoxifen | |
dc.title | Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-01-02 | |
dc.date.updated | 2022-09-05T11:44:02Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.1016/j.ejca.2022.01.003 | en_US |
rioxxterms.licenseref.startdate | 2022-03-01 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/35172273 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology/Endocrinology (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams/Endocrinology | |
pubs.publication-status | Published | |
pubs.publisher-url | http://dx.doi.org/10.1016/j.ejca.2022.01.003 | |
pubs.volume | 164 | |
icr.researchteam | Endocrinology | en_US |
dc.contributor.icrauthor | Dowsett, Mitch | |
icr.provenance | Deposited by Mr Arek Surman on 2022-09-05. Deposit type is initial. No. of files: 1. Files: 1-s2.0-S0959804922000077-main.pdf | |